Literature DB >> 7872682

Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro.

K Krasagakis1, C Garbe, P I Schrier, C E Orfanos.   

Abstract

It has been considered that the growth of human melanoma cells is positively and negatively regulated by transforming growth factors. To investigate further the role of transforming growth factor beta (TGF-beta) in melanoma biology, we analysed paracrine and autocrine growth regulatory properties of TGF-beta in normal human melanocytes and malignant melanoma cell lines in vitro. Exogenously added TGF-beta 1 potently inhibited normal melanocyte proliferation and DNA-synthesis in all cultures examined; in contrast, TGF-beta 1 inhibited only moderately or not at all the growth of cultured melanoma cells. Melanoma cell lines established from metastatic lesions were found to be less sensitive to TGF-beta 1 than those derived from primary melanomas. TGF-beta 1 resistance correlated with high levels of active TGF-beta secreted by metastatic cell lines. Inactivation of endogenously produced TGF-beta by neutralizing anti-TGF-beta antibody resulted in the stimulation of cell proliferation of a TGF-beta-sensitive primary melanoma cell line but not of a resistant metastatic one. These findings suggest that TGF-beta may function as a paracrine and autocrine growth inhibiting factor in the growth regulation of human melanocytic cells. The gradual loss of response of melanocytic cells to TGF-beta during malignant progression suggests that escape of melanoma cells from growth regulation by TGF-beta could be involved in melanoma oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7872682

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Correlation of TGF-β1 and oxidative stress in the blood of patients with melanoma: a clue to understanding melanoma progression?

Authors:  Sara Santos Bernardes; Fernando Pinheiro de Souza-Neto; Gabriella Pasqual Melo; Flávia Alessandra Guarnier; Poliana Camila Marinello; Rubens Cecchini; Alessandra L Cecchini
Journal:  Tumour Biol       Date:  2016-02-12

2.  Halofuginone inhibits the establishment and progression of melanoma bone metastases.

Authors:  Patricia Juárez; Khalid S Mohammad; Juan Juan Yin; Pierrick G J Fournier; Ryan C McKenna; Holly W Davis; Xiang H Peng; Maria Niewolna; Delphine Javelaud; John M Chirgwin; Alain Mauviel; Theresa A Guise
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

Review 3.  TGF-beta3 and cancer: a review.

Authors:  H G Laverty; L M Wakefield; N L Occleston; S O'Kane; M W J Ferguson
Journal:  Cytokine Growth Factor Rev       Date:  2009-08-04       Impact factor: 7.638

4.  Transcriptional regulation of seprase in invasive melanoma cells by transforming growth factor-β signaling.

Authors:  Shaun Tulley; Wen-Tien Chen
Journal:  J Biol Chem       Date:  2014-04-13       Impact factor: 5.157

5.  The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma.

Authors:  Laure Humbert; Mostafa Ghozlan; Lucie Canaff; Jun Tian; Jean-Jacques Lebrun
Journal:  BMC Cancer       Date:  2015-03-29       Impact factor: 4.430

6.  Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.

Authors:  Armin Maier; Anne-Lise Peille; Vincent Vuaroqueaux; Michael Lahn
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

Review 7.  Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape.

Authors:  Veronica Romano; Immacolata Belviso; Alessandro Venuta; Maria Rosaria Ruocco; Stefania Masone; Federica Aliotta; Giuseppe Fiume; Stefania Montagnani; Angelica Avagliano; Alessandro Arcucci
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

8.  Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma.

Authors:  K Krasagakis; D Thölke; B Farthmann; J Eberle; U Mansmann; C E Orfanos
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

9.  Cytokines and growth factors expressed by human cutaneous melanoma.

Authors:  Elias G Elias; Joanne H Hasskamp; Bhuvnesh K Sharma
Journal:  Cancers (Basel)       Date:  2010-05-07       Impact factor: 6.639

10.  Microenvironment‑driven resistance to B‑Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts.

Authors:  Ondřej Kodet; Barbora Dvořánková; Běla Bendlová; Vlasta Sýkorová; Ivana Krajsová; Jiří Štork; Jan Kučera; Pavol Szabo; Hynek Strnad; Michal Kolář; Čestmír Vlček; Karel Smetana; Lukáš Lacina
Journal:  Int J Mol Med       Date:  2018-02-01       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.